Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

20 Apr 2022

Abstract excerpt

Abstract Amplification of the CCNE1 locus on chromosome 19q12 is prevalent in multiple tumour types, particularly in high-grade serous ovarian cancer, uterine tumours and gastro-oesophageal cancers, where high cyclin E levels are associated with genome instability, whole-genome doubling and resistance to cytotoxic and targeted therapies 1–4 . To uncover therapeutic targets for tumours with CCNE1 amplification, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to CRISPR and Genetic Engineering
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35444283
DOI: 10.1038/s41586-022-04638-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibitionPMID 35444283Read ↗

PKMYT1 inhibition induces DNA damage and synergizes with immune checkpoint blockade in <i>CCNE1</i> -amplified gastroesophageal adenocarcinomaSemantic proximity Read ↗

Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian CancerSemantic proximity Read ↗

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsSemantic proximity Read ↗

Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 KinaseSemantic proximity Read ↗

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamicsSemantic proximity Read ↗

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalitySemantic proximity Read ↗

The CINs of Polo-Like Kinase 1 in CancerSemantic proximity Read ↗

Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low dose treatment of high-grade serous ovarian carcinomaSemantic proximity Read ↗

<i>E2F3</i> amplification primes bladder cancer cells for premature mitosisSemantic proximity Read ↗

Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancersSemantic proximity Read ↗

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalitySemantic proximity Read ↗

MCM8 variants in two patients with primary ovarian insufficiency: clinical findings and in vitro defective DNA repair revealed by an MCM8 double-mutant construct.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.